NASDAQ : ATOS
Atossa Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 2.17 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 21.66M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 18.05M | 15.96M | 13.50M | 14.04M | 12.61M | 11.31M |
| Research & Development | 21.20M | 21.18M | 14.12M | 17.33M | 15.08M | 9.21M |
| Operating Expenses | 39.25M | 37.14M | 27.62M | 31.38M | 27.69M | 20.52M |
| Operating Income | -39.25M | -37.14M | -27.62M | -31.38M | -27.69M | -20.52M |
| Interest & Investment Income | 1.55M | 2.38M | 4.05M | 4.34M | 877.00K | 6.00K |
| Other Non Operating Income (Expenses) | -6.00K | -6.00K | -223.00K | -70.00K | -146.00K | -91.00K |
| EBT Excluding Unusual Items | -37.71M | -34.77M | -23.79M | -27.10M | -26.96M | -20.61M |
| Gain (Loss) on Sale of Investments | -1.71M | -2.99M | ||||
| Pretax Income | -37.71M | -34.77M | -25.50M | -30.09M | -26.96M | -20.61M |
| Earnings From Continuing Operations | -37.71M | -34.77M | -25.50M | -30.09M | -26.96M | -20.61M |
| Net Income | -37.71M | -34.77M | -25.50M | -30.09M | -26.96M | -20.61M |
| Net Income to Common | -37.71M | -34.77M | -25.50M | -30.09M | -26.96M | -20.61M |
| Shares Outstanding (Basic) | 8.68M | 8.61M | 8.39M | 8.41M | 8.44M | 7.80M |
| Shares Outstanding (Diluted) | 8.68M | 8.61M | 8.39M | 8.41M | 8.44M | 7.80M |
| EPS (Basic) | -4.34 | -4.04 | -3.04 | -3.58 | -3.19 | -2.64 |
| EPS (Diluted) | -4.34 | -4.04 | -3.04 | -3.58 | -3.19 | -2.64 |
| Free Cash Flow | -35.78M | -29.79M | -21.05M | -20.95M | -20.79M | -16.48M |
| Free Cash Flow Per Share | -4.12 | -3.46 | -2.51 | -2.49 | -2.46 | -2.11 |
| EBITDA | -39.23M | -37.12M | -27.60M | -31.35M | -27.68M | -20.50M |
| D&A For EBITDA | 16.00K | 16.00K | 17.00K | 23.00K | 8.00K | 23.00K |
| EBIT | -39.25M | -37.14M | -27.62M | -31.38M | -27.69M | -20.52M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 26.09M | 41.30M | 71.08M | 88.46M | 110.89M | 136.38M |
| Cash & Short-Term Investments | 26.09M | 41.30M | 71.08M | 88.46M | 110.89M | 136.38M |
| Other Receivables | 743.00K | 1.07M | ||||
| Receivables | 743.00K | 1.07M | ||||
| Inventory | 3.01M | 3.08M | 2.10M | 1.49M | 5.25M | |
| Prepaid Expenses | 568.00K | 585.00K | 696.00K | 1.29M | 1.21M | 2.49M |
| Restricted Cash | 110.00K | 110.00K | 110.00K | 110.00K | 110.00K | 110.00K |
| Other Current Assets | 1.23M | 543.00K | 469.00K | 867.00K | 1.19M | |
| Total Current Assets | 31.01M | 45.62M | 74.46M | 92.22M | 118.20M | 141.24M |
| Long-Term Investments | 1.71M | 4.70M | ||||
| Other Long-Term Assets | 1.27M | 1.99M | 1.99M | 2.32M | 635.00K | 22.00K |
| Total Assets | 32.28M | 47.61M | 76.44M | 96.25M | 123.53M | 141.26M |
| Accounts Payable | 1.98M | 4.29M | 679.00K | 806.00K | 2.96M | 1.72M |
| Accrued Expenses | 2.35M | 2.87M | 2.78M | 2.63M | 2.58M | 1.39M |
| Other Current Liabilities | 1.12M | 1.10M | 1.51M | 1.80M | 19.00K | 21.00K |
| Total Current Liabilities | 5.45M | 8.26M | 4.97M | 5.24M | 5.57M | 3.13M |
| Total Liabilities | 5.45M | 8.26M | 4.97M | 5.24M | 5.57M | 3.13M |
| Common Stock | 1.80M | 1.55M | 1.55M | 22.79M | 22.79M | 22.79M |
| Additional Paid-In Capital | 291.15M | 285.84M | 283.19M | 255.99M | 251.37M | 244.00M |
| Retained Earnings | -264.64M | -246.56M | -211.79M | -186.29M | -156.19M | -129.23M |
| Treasury Stock | -1.48M | -1.48M | -1.48M | -1.48M | ||
| Total Common Equity | 26.83M | 39.35M | 71.48M | 91.02M | 117.96M | 137.55M |
| Shareholders' Equity | 26.83M | 39.35M | 71.48M | 91.02M | 117.96M | 138.14M |
| Total Liabilities & Equity | 32.28M | 47.61M | 76.44M | 96.25M | 123.53M | 141.26M |
| Net Cash (Debt) | 26.09M | 41.30M | 71.08M | 88.46M | 110.89M | 136.38M |
| Net Cash Per Share | 3.01 | 4.80 | 8.47 | 10.52 | 13.14 | 17.49 |
| Filing Date Shares Outstanding | 9.98M | 8.61M | 8.61M | 8.35M | 8.44M | 8.44M |
| Total Common Shares Outstanding | 9.98M | 8.61M | 8.61M | 8.35M | 8.44M | 8.44M |
| Working Capital | 25.56M | 37.36M | 69.49M | 86.98M | 112.63M | 138.11M |
| Book Value Per Share | 2.69 | 4.57 | 8.30 | 10.90 | 13.97 | 16.29 |
| Tangible Book Value | 26.83M | 39.35M | 71.48M | 91.02M | 117.96M | 137.55M |
| Tangible Book Value Per Share | 2.69 | 4.57 | 8.30 | 10.90 | 13.97 | 16.29 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -37.71M | -34.77M | -25.50M | -30.09M | -26.96M | -20.61M |
| Depreciation & Amortization | 16.00K | 16.00K | 17.00K | 23.00K | 8.00K | 23.00K |
| Loss (Gain) From Sale of Assets | 7.00K | |||||
| Loss (Gain) From Sale of Investments | 1.71M | 2.99M | ||||
| Stock-Based Compensation | 2.82M | 2.65M | 2.29M | 4.62M | 6.79M | 5.27M |
| Other Operating Activities | 3.00K | |||||
| Change in Inventory | 462.00K | -983.00K | -611.00K | 2.54M | ||
| Change in Accounts Payable | -34.00K | 3.61M | -127.00K | -2.16M | 1.25M | 128.00K |
| Change in Other Net Operating Assets | -1.33M | -285.00K | 1.19M | 1.13M | -1.85M | -1.28M |
| Operating Cash Flow | -35.77M | -29.76M | -21.03M | -20.94M | -20.76M | -16.47M |
| Capital Expenditures | -14.00K | -23.00K | -19.00K | -14.00K | -27.00K | -9.00K |
| Investment in Securities | -4.70M | |||||
| Investing Cash Flow | -14.00K | -23.00K | -19.00K | -14.00K | -4.73M | -9.00K |
| Issuance of Common Stock | 4.52M | 3.67M | 113.88M | |||
| Repurchase of Common Stock | -1.48M | -573.00K | ||||
| Financing Cash Flow | 4.02M | 3.67M | -1.48M | 113.30M | ||
| Net Cash Flow | -31.76M | -29.79M | -17.38M | -22.43M | -25.49M | 96.82M |
| Free Cash Flow | -35.78M | -29.79M | -21.05M | -20.95M | -20.79M | -16.48M |
| Free Cash Flow Per Share | -4.12 | -3.46 | -2.51 | -2.49 | -2.46 | -2.11 |
| Levered Free Cash Flow | -23.33M | -18.23M | -14.86M | -11.76M | -10.54M | -21.72M |
| Unlevered Free Cash Flow | -23.33M | -18.23M | -14.86M | -11.76M | -10.54M | -21.72M |
| Change in Working Capital | -900.00K | 2.35M | 448.00K | 1.52M | -599.00K | -1.16M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 21.66M | 76.21M | 118.77M | 110.27M | 66.92M | 202.60M |
| Enterprise Value | -4.44M | 24.37M | 44.00M | 16.82M | -49.86M | 63.14M |
| Last Close Price | 2.17 | 8.85 | 14.16 | 13.20 | 7.93 | 24.00 |
| Forward PE | 181.67 | 181.67 | 181.67 | 181.67 | 181.67 | |
| PB Ratio | 0.81 | 1.94 | 1.66 | 1.21 | 0.57 | 1.47 |
| P/TBV Ratio | 0.81 | 1.94 | 1.66 | 1.21 | 0.57 | 1.47 |
| PEG Ratio | 2.42 | 2.42 | 2.42 | 2.42 | 2.42 | |
| Net Debt / Equity Ratio | -0.97 | -1.05 | -0.99 | -0.97 | -0.94 | -0.99 |
| Net Debt / EBITDA Ratio | 0.67 | 1.11 | 2.58 | 2.82 | 4.01 | 6.65 |
| Net Debt / FCF Ratio | 0.73 | 1.39 | 3.38 | 4.22 | 5.33 | 8.28 |
| Quick Ratio | 4.79 | 5.00 | 14.31 | 16.89 | 20.05 | 43.97 |
| Current Ratio | 5.69 | 5.53 | 14.99 | 17.61 | 21.23 | 45.18 |
| Return on Equity (ROE) | -89.23% | -62.74% | -31.39% | -28.80% | -21.05% | -24.93% |
| Return on Assets (ROA) | -50.69% | -37.43% | -19.99% | -17.84% | -13.07% | -13.93% |
| Return on Capital Employed (ROCE) | -146.30% | -94.40% | -38.60% | -34.50% | -23.50% | -14.90% |
| Earnings Yield | -200.13% | -45.62% | -21.47% | -27.29% | -40.29% | -10.17% |
| FCF Yield | -165.24% | -39.08% | -17.72% | -19.00% | -31.06% | -8.13% |
| Buyback Yield / Dilution | -1.95% | -2.63% | 0.18% | 0.43% | -8.27% | -934.13% |